JP2013503905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503905A5 JP2013503905A5 JP2012528103A JP2012528103A JP2013503905A5 JP 2013503905 A5 JP2013503905 A5 JP 2013503905A5 JP 2012528103 A JP2012528103 A JP 2012528103A JP 2012528103 A JP2012528103 A JP 2012528103A JP 2013503905 A5 JP2013503905 A5 JP 2013503905A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- compound
- sulfur
- oxygen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C/*(/*C*[C@@](C1)C2=CCC(IC3CCCCCCCC3)=CC=C/C=C2)=C\N1c1nc(*)nc2c1cc[n]2 Chemical compound C/*(/*C*[C@@](C1)C2=CCC(IC3CCCCCCCC3)=CC=C/C=C2)=C\N1c1nc(*)nc2c1cc[n]2 0.000 description 3
- OBSLLHNATPQFMJ-UHFFFAOYSA-N Cc1c[s]c(C)n1 Chemical compound Cc1c[s]c(C)n1 OBSLLHNATPQFMJ-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24001109P | 2009-09-04 | 2009-09-04 | |
| US61/240,011 | 2009-09-04 | ||
| PCT/US2010/047883 WO2011029046A1 (en) | 2009-09-04 | 2010-09-03 | Bruton's tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027205A Division JP2015091898A (ja) | 2009-09-04 | 2015-02-16 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503905A JP2013503905A (ja) | 2013-02-04 |
| JP2013503905A5 true JP2013503905A5 (enExample) | 2013-10-17 |
| JP5699149B2 JP5699149B2 (ja) | 2015-04-08 |
Family
ID=43649668
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528103A Expired - Fee Related JP5699149B2 (ja) | 2009-09-04 | 2010-09-03 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2015027205A Withdrawn JP2015091898A (ja) | 2009-09-04 | 2015-02-16 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2017137018A Expired - Fee Related JP6326533B2 (ja) | 2009-09-04 | 2017-07-13 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2018078461A Expired - Fee Related JP6673969B2 (ja) | 2009-09-04 | 2018-04-16 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2020000042A Withdrawn JP2020055871A (ja) | 2009-09-04 | 2020-01-05 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2022033553A Pending JP2022071149A (ja) | 2009-09-04 | 2022-03-04 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027205A Withdrawn JP2015091898A (ja) | 2009-09-04 | 2015-02-16 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2017137018A Expired - Fee Related JP6326533B2 (ja) | 2009-09-04 | 2017-07-13 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2018078461A Expired - Fee Related JP6673969B2 (ja) | 2009-09-04 | 2018-04-16 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2020000042A Withdrawn JP2020055871A (ja) | 2009-09-04 | 2020-01-05 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| JP2022033553A Pending JP2022071149A (ja) | 2009-09-04 | 2022-03-04 | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8785440B2 (enExample) |
| EP (2) | EP3461824B1 (enExample) |
| JP (6) | JP5699149B2 (enExample) |
| CN (3) | CN112300172B (enExample) |
| AR (2) | AR078320A1 (enExample) |
| AU (3) | AU2010289313B2 (enExample) |
| CA (2) | CA3082212C (enExample) |
| DK (1) | DK2473049T3 (enExample) |
| ES (2) | ES2891543T3 (enExample) |
| HU (1) | HUE043522T2 (enExample) |
| NZ (1) | NZ598985A (enExample) |
| PL (1) | PL2473049T3 (enExample) |
| PT (1) | PT2473049T (enExample) |
| TW (2) | TWI711610B (enExample) |
| WO (1) | WO2011029046A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461824B1 (en) * | 2009-09-04 | 2021-08-25 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| MX2012013465A (es) * | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
| MX2013001970A (es) * | 2010-08-20 | 2013-08-09 | Hutchison Medipharma Ltd | Compuestos de pirrolopirimidina y usos de los mismos. |
| EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
| LT2718270T (lt) * | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| BR112014000314A2 (pt) * | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
| EP2731612A4 (en) | 2011-07-13 | 2015-04-08 | Pharmacyclics Inc | BRUTON TYROSINE KINASE HEMMER |
| CA3173988A1 (en) | 2011-10-11 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic bax |
| EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| US8722676B2 (en) * | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
| JP5976828B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物 |
| BR112014010460A2 (pt) * | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP2802328B1 (en) | 2012-01-09 | 2018-03-07 | X-Chem, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| AU2013250726B2 (en) * | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN102702110A (zh) * | 2012-05-24 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4-氨基-5,6-二氯嘧啶的制备方法 |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| JP6139690B2 (ja) * | 2012-10-26 | 2017-05-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルートンチロシンキナーゼの阻害剤 |
| MD20150035A2 (ro) * | 2012-11-02 | 2015-10-31 | Pfizer Inc. | Inhibitori de tirozinkinaza Bruton |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| EA028756B1 (ru) | 2013-04-25 | 2017-12-29 | Бэйджин, Лтд. | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы |
| BR112015032330B1 (pt) | 2013-06-26 | 2019-01-22 | Abbvie Inc. | carboxamidas primárias como inibidores de bkt |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| ME02883B (me) | 2013-12-05 | 2018-04-20 | Pfizer | PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI |
| SI3080103T1 (sl) * | 2013-12-11 | 2018-11-30 | Biogen Ma Inc. | Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| JP6761815B2 (ja) | 2015-05-01 | 2020-09-30 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド |
| KR102404759B1 (ko) * | 2016-05-16 | 2022-05-31 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| US11174243B2 (en) * | 2016-07-21 | 2021-11-16 | Sunesis Pharmaceuticals, Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
| SG11201901141WA (en) | 2016-08-16 | 2019-03-28 | Beigene Ltd | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| CN118252927A (zh) | 2016-08-19 | 2024-06-28 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CA3037364A1 (en) | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| JOP20190233A1 (ar) * | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| US11186554B2 (en) | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| JP2020525411A (ja) | 2017-06-26 | 2020-08-27 | ベイジーン リミテッド | 肝細胞癌のための免疫療法 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| AU2018321291A1 (en) | 2017-08-21 | 2020-03-26 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治宫颈炎的活性化合物 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| CA3100503A1 (en) * | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
| US20220362357A1 (en) | 2018-08-31 | 2022-11-17 | Stichting Radboud Universitair Medisch Centrum | Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof |
| EP3852879A1 (en) | 2018-09-21 | 2021-07-28 | Pfizer Inc. | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
| CN109369513B (zh) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | 一种fbdd常用分子片段的制备方法 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JOP20220160A1 (ar) | 2019-12-20 | 2023-01-30 | Nuevolution As | مركبات فعّالة نحو مستقبلات نووية |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| CN113416847B (zh) * | 2021-07-05 | 2022-05-31 | 昆明理工大学 | 一种将提钒尾渣资源化、减量化、无害化处理的方法 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| IL319392A (en) | 2022-10-18 | 2025-05-01 | Pfizer | Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations |
| EP4604955A1 (en) | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6919178B2 (en) * | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| HUP0300850A2 (hu) | 2000-03-17 | 2003-07-28 | Bristol-Myers Squibb Pharma Company | Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| EA006153B1 (ru) | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2003037898A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| EP1599468B1 (en) * | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| CN1835943B (zh) * | 2003-01-14 | 2012-03-07 | 阿伦纳药品公司 | 作为代谢调节剂的1，2，3-三取代的芳基和杂芳基衍生物及其应用 |
| ES2344007T3 (es) | 2003-10-14 | 2010-08-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibidores proteina quinasa. |
| US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| MX337817B (es) | 2004-11-04 | 2011-11-04 | Vertex Pharma | Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas. |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
| WO2006071875A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| MX362412B (es) * | 2005-11-01 | 2019-01-15 | Targegen Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
| CN101378807A (zh) | 2005-12-21 | 2009-03-04 | 先灵公司 | H3拮抗剂/反相激动剂与食欲抑制剂的组合 |
| WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| JP2009544732A (ja) | 2006-07-26 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | ウンデカプレニルピロホスフェートシンターゼの阻害剤 |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| WO2008108957A2 (en) | 2007-03-02 | 2008-09-12 | Schering Corporation | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| US8093239B2 (en) * | 2007-06-01 | 2012-01-10 | Glaxosmithkline Llc | Imidazopyridine kinase inhibitors |
| NZ586916A (en) | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
| MX2010011788A (es) | 2008-04-29 | 2011-05-30 | Immunexcite Inc | Composiciones inmunomoduladoras y metodos de uso de las mismas. |
| EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| CN102325753B (zh) | 2008-12-19 | 2014-09-10 | 百时美施贵宝公司 | 用作激酶抑制剂的咔唑甲酰胺化合物 |
| EP3255047B1 (en) | 2009-01-06 | 2021-06-30 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders |
| ES2565205T3 (es) | 2009-05-25 | 2016-04-01 | Sandoz Ag | Método para la producción de ceftobiprol medocaril |
| EP3461824B1 (en) * | 2009-09-04 | 2021-08-25 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| US8685880B2 (en) | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
| EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
| EP2858500A4 (en) * | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | BRUTON TYROSINE KINASE HEMMER |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| SI3080103T1 (sl) * | 2013-12-11 | 2018-11-30 | Biogen Ma Inc. | Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije |
| WO2015089327A1 (en) * | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| US20170298446A1 (en) | 2014-10-03 | 2017-10-19 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
| US11174243B2 (en) * | 2016-07-21 | 2021-11-16 | Sunesis Pharmaceuticals, Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
| WO2022212893A1 (en) * | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023081709A1 (en) * | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
-
2010
- 2010-09-03 EP EP18204302.6A patent/EP3461824B1/en active Active
- 2010-09-03 CN CN202010504358.3A patent/CN112300172B/zh not_active Expired - Fee Related
- 2010-09-03 CN CN201610915859.4A patent/CN107011330B/zh not_active Expired - Fee Related
- 2010-09-03 ES ES18204302T patent/ES2891543T3/es active Active
- 2010-09-03 TW TW105123517A patent/TWI711610B/zh not_active IP Right Cessation
- 2010-09-03 DK DK10814585.5T patent/DK2473049T3/en active
- 2010-09-03 PL PL10814585T patent/PL2473049T3/pl unknown
- 2010-09-03 EP EP10814585.5A patent/EP2473049B1/en active Active
- 2010-09-03 AU AU2010289313A patent/AU2010289313B2/en not_active Ceased
- 2010-09-03 WO PCT/US2010/047883 patent/WO2011029046A1/en not_active Ceased
- 2010-09-03 PT PT10814585T patent/PT2473049T/pt unknown
- 2010-09-03 NZ NZ598985A patent/NZ598985A/xx not_active IP Right Cessation
- 2010-09-03 JP JP2012528103A patent/JP5699149B2/ja not_active Expired - Fee Related
- 2010-09-03 US US13/393,192 patent/US8785440B2/en active Active
- 2010-09-03 TW TW099129993A patent/TWI557127B/zh not_active IP Right Cessation
- 2010-09-03 CN CN201080049405.4A patent/CN102711473B/zh not_active Expired - Fee Related
- 2010-09-03 CA CA3082212A patent/CA3082212C/en active Active
- 2010-09-03 HU HUE10814585A patent/HUE043522T2/hu unknown
- 2010-09-03 ES ES10814585T patent/ES2711936T3/es active Active
- 2010-09-03 AR ARP100103238A patent/AR078320A1/es active IP Right Grant
- 2010-09-03 CA CA2771822A patent/CA2771822C/en active Active
-
2014
- 2014-06-26 US US14/316,710 patent/US9249146B2/en active Active
-
2015
- 2015-02-16 JP JP2015027205A patent/JP2015091898A/ja not_active Withdrawn
-
2016
- 2016-01-25 US US15/006,061 patent/US9790229B2/en active Active
- 2016-04-22 AU AU2016202601A patent/AU2016202601B2/en not_active Ceased
-
2017
- 2017-07-13 JP JP2017137018A patent/JP6326533B2/ja not_active Expired - Fee Related
- 2017-09-07 US US15/698,171 patent/US10577374B2/en active Active
-
2018
- 2018-03-07 AU AU2018201668A patent/AU2018201668B2/en not_active Ceased
- 2018-04-16 JP JP2018078461A patent/JP6673969B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-05 JP JP2020000042A patent/JP2020055871A/ja not_active Withdrawn
- 2020-01-21 US US16/748,410 patent/US20200399283A1/en not_active Abandoned
-
2021
- 2021-05-11 AR ARP210101299A patent/AR122069A2/es not_active Application Discontinuation
-
2022
- 2022-03-04 JP JP2022033553A patent/JP2022071149A/ja active Pending
- 2022-05-12 US US17/743,214 patent/US20230046457A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,940 patent/US20240246988A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503905A5 (enExample) | ||
| JP2013506715A5 (enExample) | ||
| RU2012118667A (ru) | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 | |
| JP2019527718A5 (enExample) | ||
| JP2007524707A5 (enExample) | ||
| JP6538656B2 (ja) | ５’−ヌクレオチダーゼ阻害剤およびその治療的使用 | |
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| JP2016509047A5 (enExample) | ||
| JP2014507421A5 (enExample) | ||
| JP2014513101A5 (enExample) | ||
| JP2008530099A5 (enExample) | ||
| CA2422367A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| JP2004509113A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| NO20083059L (no) | Pyrimidinderivater | |
| JP2004509118A5 (enExample) | ||
| JP2004509116A5 (enExample) | ||
| JP2006515313A5 (enExample) | ||
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2013508288A5 (enExample) | ||
| RU2017104898A (ru) | Дигидроптеридиноновые производные и их применения | |
| CA2406392A1 (en) | Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis | |
| KR20130099064A (ko) | (아자)인돌리진 유도체 및 그 의약용도 | |
| RU2013147629A (ru) | Соединения для лечения метаболического синдрома | |
| RU2019142472A (ru) | Глюкуронидные пролекарства ингибиторов янус-киназы |